Efficacy and safety of sotagliflozin adjuvant therapy for type 1 diabetes mellitus: A systematic review and meta-analysis
To systematically evaluate the efficacy and safety of sotagliflozin (SOTA) adjuvant therapy for type 1 diabetes mellitus (T1DM). Through April 2019, the Web of Science, PubMed, Cochrane Library, Embase, and China National Knowledge Infrastructure databases were electronically searched to identify ra...
Gespeichert in:
| Veröffentlicht in: | Medicine (Baltimore) 2020-08, Vol.99 (33), p.e20875-e20875 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | e20875 |
|---|---|
| container_issue | 33 |
| container_start_page | e20875 |
| container_title | Medicine (Baltimore) |
| container_volume | 99 |
| creator | Chen, Mao-Bing Xu, Rui-Jun Zheng, Qi-Han Zheng, Xu-Wen Wang, Hua |
| description | To systematically evaluate the efficacy and safety of sotagliflozin (SOTA) adjuvant therapy for type 1 diabetes mellitus (T1DM).
Through April 2019, the Web of Science, PubMed, Cochrane Library, Embase, and China National Knowledge Infrastructure databases were electronically searched to identify randomized controlled trials exploring SOTA adjuvant therapy for T1DM. Strict screening and quality evaluations of the obtained literature were performed independently by 2 researchers. Outcome indexes were extracted, and a meta-analysis of the data was performed using Revman 5.3 software.
A total of 7 randomized controlled trials were included. The meta-analysis results showed that compared with the patients in the placebo group, the patients in the SOTA group had a lower hemoglobin A1c (mean difference [MD] = -0.28, 95% confidence interval [CI] [-0.34, -0.22], P |
| doi_str_mv | 10.1097/MD.0000000000020875 |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7437859</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>32871972</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3556-a531002bc8ecfd5dc3b0588caef4368ec8b3044a113e2d179ad0a6d998687fc93</originalsourceid><addsrcrecordid>eNpdkdtu1DAQhi0EotvCEyAhv0BaO45jhwukqi0HqRU3cG1N7HHXxUlWtndX4enJdqEc5makf-b_RjNDyBvOzjnr1MXd9Tn7EzXTSj4jKy5FW8mubZ6T1aLKSnWqOSGnOT8wxoWqm5fkRNRa8U7VKzLfeB8s2JnC6GgGj2Wmk6d5KnAfg4_TjzBScA_bHYyFljUm2MzUT4mWeYOUUxegx4KZDhhjKNv8jl7SPOeCA5RgacJdwP0jfsACFYwQ5xzyK_LCQ8z4-lc-I98-3Hy9-lTdfvn4-erytrJCyrYCKfiyR281Wu-ks6JnUmsL6BvRLqLuBWsa4Fxg7bjqwDFoXdfpVitvO3FG3h-5m20_oLM4lgTRbFIYIM1mgmD-rYxhbe6nnVGNUFoeAOIIsGnKOaF_8nJmDp8wd9fm_08srrd_j33y_D790tAcG_ZTLJjy97jdYzJrhFjWjzypurqqFx7TvGHVQWrFT4hulyk</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Efficacy and safety of sotagliflozin adjuvant therapy for type 1 diabetes mellitus: A systematic review and meta-analysis</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Wolters Kluwer Open Health</source><source>IngentaConnect Free/Open Access Journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Chen, Mao-Bing ; Xu, Rui-Jun ; Zheng, Qi-Han ; Zheng, Xu-Wen ; Wang, Hua</creator><creatorcontrib>Chen, Mao-Bing ; Xu, Rui-Jun ; Zheng, Qi-Han ; Zheng, Xu-Wen ; Wang, Hua</creatorcontrib><description><![CDATA[To systematically evaluate the efficacy and safety of sotagliflozin (SOTA) adjuvant therapy for type 1 diabetes mellitus (T1DM).
Through April 2019, the Web of Science, PubMed, Cochrane Library, Embase, and China National Knowledge Infrastructure databases were electronically searched to identify randomized controlled trials exploring SOTA adjuvant therapy for T1DM. Strict screening and quality evaluations of the obtained literature were performed independently by 2 researchers. Outcome indexes were extracted, and a meta-analysis of the data was performed using Revman 5.3 software.
A total of 7 randomized controlled trials were included. The meta-analysis results showed that compared with the patients in the placebo group, the patients in the SOTA group had a lower hemoglobin A1c (mean difference [MD] = -0.28, 95% confidence interval [CI] [-0.34, -0.22], P < .01), lower total daily insulin use (MD = -8.89, 95% CI [-11.64, -6.13], P < .01), faster weight loss (MD = -3.03, 95% CI [-3.79, -2.26], P < .01), better fasting blood glucose and 2-hour postprandial blood glucose control (MD = -0.75, 95% CI [-1.04, -0.45], P < .01; MD = -2.42, 95% CI [-3.17, -1.67], P < .01), and a higher rate of well-controlled glucose levels (relative risk = 1.75, 95% CI [1.55, 1.99], P < .01), while no significant difference in the incidence of severe hypoglycemic events was found between the SOTA and placebo groups (risk difference [RD] = -0.01, 95% CI [-0.02, 0.00], P = .13). The incidence of diabetic ketoacidosis was higher in the SOTA group than in the placebo group (RD = 0.03, 95% CI [0.02, 0.04], P < .01). The incidence of genital mycotic infection was higher in the SOTA group than in the placebo group (RD = 0.06, 95% CI [0.05, 0.08], P < .01). No significant difference in the incidence of urinary tract infections was detected between the SOTA group and the placebo group (RD = 0.00, 95% CI [-0.01, 0.01], P = 0.97).
SOTA is a potential drug for the treatment of T1DM and is effective for controlling blood sugar. The main adverse reactions to SOTA are genital mycotic infections and diabetic ketoacidosis. We must further assess the severity of diabetic ketoacidosis caused by SOTA.]]></description><identifier>ISSN: 0025-7974</identifier><identifier>EISSN: 1536-5964</identifier><identifier>DOI: 10.1097/MD.0000000000020875</identifier><identifier>PMID: 32871972</identifier><language>eng</language><publisher>United States: Lippincott Williams & Wilkins</publisher><subject>Chemotherapy, Adjuvant ; Diabetes Mellitus, Type 1 - drug therapy ; Glycosides - adverse effects ; Glycosides - therapeutic use ; Humans ; Randomized Controlled Trials as Topic ; Sodium-Glucose Transporter 1 - adverse effects ; Sodium-Glucose Transporter 1 - therapeutic use ; Systematic Review and Meta-Analysis</subject><ispartof>Medicine (Baltimore), 2020-08, Vol.99 (33), p.e20875-e20875</ispartof><rights>Lippincott Williams & Wilkins</rights><rights>Copyright © 2020 the Author(s). Published by Wolters Kluwer Health, Inc. 2020</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c3556-a531002bc8ecfd5dc3b0588caef4368ec8b3044a113e2d179ad0a6d998687fc93</cites><orcidid>0000-0001-5037-9870</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7437859/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7437859/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,860,881,27903,27904,53769,53771</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32871972$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Chen, Mao-Bing</creatorcontrib><creatorcontrib>Xu, Rui-Jun</creatorcontrib><creatorcontrib>Zheng, Qi-Han</creatorcontrib><creatorcontrib>Zheng, Xu-Wen</creatorcontrib><creatorcontrib>Wang, Hua</creatorcontrib><title>Efficacy and safety of sotagliflozin adjuvant therapy for type 1 diabetes mellitus: A systematic review and meta-analysis</title><title>Medicine (Baltimore)</title><addtitle>Medicine (Baltimore)</addtitle><description><![CDATA[To systematically evaluate the efficacy and safety of sotagliflozin (SOTA) adjuvant therapy for type 1 diabetes mellitus (T1DM).
Through April 2019, the Web of Science, PubMed, Cochrane Library, Embase, and China National Knowledge Infrastructure databases were electronically searched to identify randomized controlled trials exploring SOTA adjuvant therapy for T1DM. Strict screening and quality evaluations of the obtained literature were performed independently by 2 researchers. Outcome indexes were extracted, and a meta-analysis of the data was performed using Revman 5.3 software.
A total of 7 randomized controlled trials were included. The meta-analysis results showed that compared with the patients in the placebo group, the patients in the SOTA group had a lower hemoglobin A1c (mean difference [MD] = -0.28, 95% confidence interval [CI] [-0.34, -0.22], P < .01), lower total daily insulin use (MD = -8.89, 95% CI [-11.64, -6.13], P < .01), faster weight loss (MD = -3.03, 95% CI [-3.79, -2.26], P < .01), better fasting blood glucose and 2-hour postprandial blood glucose control (MD = -0.75, 95% CI [-1.04, -0.45], P < .01; MD = -2.42, 95% CI [-3.17, -1.67], P < .01), and a higher rate of well-controlled glucose levels (relative risk = 1.75, 95% CI [1.55, 1.99], P < .01), while no significant difference in the incidence of severe hypoglycemic events was found between the SOTA and placebo groups (risk difference [RD] = -0.01, 95% CI [-0.02, 0.00], P = .13). The incidence of diabetic ketoacidosis was higher in the SOTA group than in the placebo group (RD = 0.03, 95% CI [0.02, 0.04], P < .01). The incidence of genital mycotic infection was higher in the SOTA group than in the placebo group (RD = 0.06, 95% CI [0.05, 0.08], P < .01). No significant difference in the incidence of urinary tract infections was detected between the SOTA group and the placebo group (RD = 0.00, 95% CI [-0.01, 0.01], P = 0.97).
SOTA is a potential drug for the treatment of T1DM and is effective for controlling blood sugar. The main adverse reactions to SOTA are genital mycotic infections and diabetic ketoacidosis. We must further assess the severity of diabetic ketoacidosis caused by SOTA.]]></description><subject>Chemotherapy, Adjuvant</subject><subject>Diabetes Mellitus, Type 1 - drug therapy</subject><subject>Glycosides - adverse effects</subject><subject>Glycosides - therapeutic use</subject><subject>Humans</subject><subject>Randomized Controlled Trials as Topic</subject><subject>Sodium-Glucose Transporter 1 - adverse effects</subject><subject>Sodium-Glucose Transporter 1 - therapeutic use</subject><subject>Systematic Review and Meta-Analysis</subject><issn>0025-7974</issn><issn>1536-5964</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpdkdtu1DAQhi0EotvCEyAhv0BaO45jhwukqi0HqRU3cG1N7HHXxUlWtndX4enJdqEc5makf-b_RjNDyBvOzjnr1MXd9Tn7EzXTSj4jKy5FW8mubZ6T1aLKSnWqOSGnOT8wxoWqm5fkRNRa8U7VKzLfeB8s2JnC6GgGj2Wmk6d5KnAfg4_TjzBScA_bHYyFljUm2MzUT4mWeYOUUxegx4KZDhhjKNv8jl7SPOeCA5RgacJdwP0jfsACFYwQ5xzyK_LCQ8z4-lc-I98-3Hy9-lTdfvn4-erytrJCyrYCKfiyR281Wu-ks6JnUmsL6BvRLqLuBWsa4Fxg7bjqwDFoXdfpVitvO3FG3h-5m20_oLM4lgTRbFIYIM1mgmD-rYxhbe6nnVGNUFoeAOIIsGnKOaF_8nJmDp8wd9fm_08srrd_j33y_D790tAcG_ZTLJjy97jdYzJrhFjWjzypurqqFx7TvGHVQWrFT4hulyk</recordid><startdate>20200814</startdate><enddate>20200814</enddate><creator>Chen, Mao-Bing</creator><creator>Xu, Rui-Jun</creator><creator>Zheng, Qi-Han</creator><creator>Zheng, Xu-Wen</creator><creator>Wang, Hua</creator><general>Lippincott Williams & Wilkins</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-5037-9870</orcidid></search><sort><creationdate>20200814</creationdate><title>Efficacy and safety of sotagliflozin adjuvant therapy for type 1 diabetes mellitus: A systematic review and meta-analysis</title><author>Chen, Mao-Bing ; Xu, Rui-Jun ; Zheng, Qi-Han ; Zheng, Xu-Wen ; Wang, Hua</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3556-a531002bc8ecfd5dc3b0588caef4368ec8b3044a113e2d179ad0a6d998687fc93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Chemotherapy, Adjuvant</topic><topic>Diabetes Mellitus, Type 1 - drug therapy</topic><topic>Glycosides - adverse effects</topic><topic>Glycosides - therapeutic use</topic><topic>Humans</topic><topic>Randomized Controlled Trials as Topic</topic><topic>Sodium-Glucose Transporter 1 - adverse effects</topic><topic>Sodium-Glucose Transporter 1 - therapeutic use</topic><topic>Systematic Review and Meta-Analysis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Chen, Mao-Bing</creatorcontrib><creatorcontrib>Xu, Rui-Jun</creatorcontrib><creatorcontrib>Zheng, Qi-Han</creatorcontrib><creatorcontrib>Zheng, Xu-Wen</creatorcontrib><creatorcontrib>Wang, Hua</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Medicine (Baltimore)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Chen, Mao-Bing</au><au>Xu, Rui-Jun</au><au>Zheng, Qi-Han</au><au>Zheng, Xu-Wen</au><au>Wang, Hua</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Efficacy and safety of sotagliflozin adjuvant therapy for type 1 diabetes mellitus: A systematic review and meta-analysis</atitle><jtitle>Medicine (Baltimore)</jtitle><addtitle>Medicine (Baltimore)</addtitle><date>2020-08-14</date><risdate>2020</risdate><volume>99</volume><issue>33</issue><spage>e20875</spage><epage>e20875</epage><pages>e20875-e20875</pages><issn>0025-7974</issn><eissn>1536-5964</eissn><abstract><![CDATA[To systematically evaluate the efficacy and safety of sotagliflozin (SOTA) adjuvant therapy for type 1 diabetes mellitus (T1DM).
Through April 2019, the Web of Science, PubMed, Cochrane Library, Embase, and China National Knowledge Infrastructure databases were electronically searched to identify randomized controlled trials exploring SOTA adjuvant therapy for T1DM. Strict screening and quality evaluations of the obtained literature were performed independently by 2 researchers. Outcome indexes were extracted, and a meta-analysis of the data was performed using Revman 5.3 software.
A total of 7 randomized controlled trials were included. The meta-analysis results showed that compared with the patients in the placebo group, the patients in the SOTA group had a lower hemoglobin A1c (mean difference [MD] = -0.28, 95% confidence interval [CI] [-0.34, -0.22], P < .01), lower total daily insulin use (MD = -8.89, 95% CI [-11.64, -6.13], P < .01), faster weight loss (MD = -3.03, 95% CI [-3.79, -2.26], P < .01), better fasting blood glucose and 2-hour postprandial blood glucose control (MD = -0.75, 95% CI [-1.04, -0.45], P < .01; MD = -2.42, 95% CI [-3.17, -1.67], P < .01), and a higher rate of well-controlled glucose levels (relative risk = 1.75, 95% CI [1.55, 1.99], P < .01), while no significant difference in the incidence of severe hypoglycemic events was found between the SOTA and placebo groups (risk difference [RD] = -0.01, 95% CI [-0.02, 0.00], P = .13). The incidence of diabetic ketoacidosis was higher in the SOTA group than in the placebo group (RD = 0.03, 95% CI [0.02, 0.04], P < .01). The incidence of genital mycotic infection was higher in the SOTA group than in the placebo group (RD = 0.06, 95% CI [0.05, 0.08], P < .01). No significant difference in the incidence of urinary tract infections was detected between the SOTA group and the placebo group (RD = 0.00, 95% CI [-0.01, 0.01], P = 0.97).
SOTA is a potential drug for the treatment of T1DM and is effective for controlling blood sugar. The main adverse reactions to SOTA are genital mycotic infections and diabetic ketoacidosis. We must further assess the severity of diabetic ketoacidosis caused by SOTA.]]></abstract><cop>United States</cop><pub>Lippincott Williams & Wilkins</pub><pmid>32871972</pmid><doi>10.1097/MD.0000000000020875</doi><orcidid>https://orcid.org/0000-0001-5037-9870</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0025-7974 |
| ispartof | Medicine (Baltimore), 2020-08, Vol.99 (33), p.e20875-e20875 |
| issn | 0025-7974 1536-5964 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7437859 |
| source | MEDLINE; DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Wolters Kluwer Open Health; IngentaConnect Free/Open Access Journals; PubMed Central; Alma/SFX Local Collection |
| subjects | Chemotherapy, Adjuvant Diabetes Mellitus, Type 1 - drug therapy Glycosides - adverse effects Glycosides - therapeutic use Humans Randomized Controlled Trials as Topic Sodium-Glucose Transporter 1 - adverse effects Sodium-Glucose Transporter 1 - therapeutic use Systematic Review and Meta-Analysis |
| title | Efficacy and safety of sotagliflozin adjuvant therapy for type 1 diabetes mellitus: A systematic review and meta-analysis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-25T07%3A54%3A05IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Efficacy%20and%20safety%20of%20sotagliflozin%20adjuvant%20therapy%20for%20type%201%20diabetes%20mellitus:%20A%20systematic%20review%20and%20meta-analysis&rft.jtitle=Medicine%20(Baltimore)&rft.au=Chen,%20Mao-Bing&rft.date=2020-08-14&rft.volume=99&rft.issue=33&rft.spage=e20875&rft.epage=e20875&rft.pages=e20875-e20875&rft.issn=0025-7974&rft.eissn=1536-5964&rft_id=info:doi/10.1097/MD.0000000000020875&rft_dat=%3Cpubmed_cross%3E32871972%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/32871972&rfr_iscdi=true |